Results 11 to 20 of about 6,848 (153)
Molecular signature associated with cladribine treatment in patients with multiple sclerosis
Frontiers in Immunology, 2023 IntroductionLittle is known about the molecular profiling associated with the effect of cladribine in patients with multiple sclerosis (MS). Here, we aimed first to characterize the transcriptomic and proteomic profiles induced by cladribine in blood ...
Nicolas Fissolo +15 more
doaj +1 more source
Journal of Central Nervous System Disease, 2021 Background Patients with multiple sclerosis (MS) receiving immunomodulatory drugs were excluded from clinical trials on COVID-19 vaccines. Therefore, data regarding the efficacy of COVID-19 vaccines to induce humoral immunity in MS patients treated with ...
Christoph Grothe +2 more
doaj +1 more source
Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma
BMC Cancer, 2011 Background Cladribine or 2-chlorodeoxyadenosine (2-CDA) is a well-known purine nucleoside analog with particular activity against lymphoproliferative disorders, such as hairy cell leukemia (HCL). Its benefits in multiple myeloma (MM) remain unclear. Here
Lee Choon-Kee +6 more
doaj +1 more source
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells. [PDF]
PLoS ONE, 2015 Cladribine is a cytotoxic drug which ameliorates the clinical course of relapsing-remitting multiple sclerosis. In addition to cytotoxicity, the mode of action may include immunomodulatory mechanisms.
Melanie Korsen +4 more
doaj +1 more source
Neurology and Therapy, 2020 Immune reconstitution therapy (IRT) is an emerging management concept for multiple sclerosis, whereby a short course of treatment provides long-lasting suppression of disease activity.
Mohamed AlJumah +15 more
doaj +1 more source
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2021 Background Treatment-emergent adverse events (TEAEs) that occur close to treatment initiation may negatively affect overall tolerability and adherence. It is important to develop a clear understanding of potential early TEAEs after initiating treatment ...
Jiwon Oh +8 more
doaj +1 more source
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2023 Background Cladribine is a useful therapeutic option in RRMS with moderate to high disease activity. Its oral formulation and tolerability make it a useful alternative to infusion therapies.
Mitchell J Lycett +4 more
doaj +1 more source
A Novel One-Pot Enzyme Cascade for the Biosynthesis of Cladribine Triphosphate
Biomolecules, 2021 Cladribine triphosphate is the active compound of the anti-cancer and multiple sclerosis drug Mavenclad (cladribine). Biosynthesis of such non-natural deoxyribonucleotides is challenging but important in order to study the pharmaceutical modes of action.
Julia Frisch +2 more
doaj +1 more source
Cladribine Analogues via O6-(Benzotriazolyl) Derivatives of Guanine Nucleosides
Molecules, 2015 Cladribine, 2-chloro-2′-deoxyadenosine, is a highly efficacious, clinically used nucleoside for the treatment of hairy cell leukemia. It is also being evaluated against other lymphoid malignancies and has been a molecule of interest for well over half a ...
Sakilam Satishkumar +11 more
doaj +1 more source